ALUPENT
LOE ApproachingNDAINHALATIONSOLUTIONPriority Review
Approved
Sep 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an inhaled bronchodilator solution approved in 1980 for respiratory indications. The product is a small-molecule beta-agonist delivered via inhalation. Specific indications are not detailed in available data.
LOE Approaching
Product is in late-stage lifecycle with modest competitive pressure (30%), indicating a stable but contracting portfolio footprint requiring defensive strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALUPENT currently shows zero linked job openings and is approaching loss of exclusivity, indicating a contracting team and limited hiring. Career trajectory on this product is defensive, focused on market maintenance rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.